Not every promising discovery needs its own company. But making the right venture decision in socially responsible drug development is one of the most consequential choices an academic researcher, clinician, or principal investigator will face.
In socially responsible drug development, the question starts in a different place. Not “how do we commercialise this?” but “how do we get this to patients?” The right structure follows from that answer.
Sometimes proving clinical value is the most direct route to patient access. Sometimes a licence works better. Sometimes a venture is the only way to maintain control over pricing and accessibility. This article helps you decide which route fits your project.
What Contains a Venture Decision in socially responsible drug development?
A venture decision means creating a dedicated legal entity around your research. This entity holds intellectual property, manages development, and attracts funding. The legal structure you choose matters. A standard limited liability company works well in most cases. But newer structures like steward ownership are gaining ground in mission-driven drug development.
The key distinction: in a venture you maintain control. Over development direction, pricing, and ultimately patient access. That control comes with responsibility. You need governance, a business case, and partners who share your mission. Figure 1 illustrates why making a venture decision is important.
What Do You As Researcher Want?
Before deciding on a venture in socially responsible drug development, be honest about your own goals and your project’s potential. This shapes everything.
Ask yourself these questions:
Is the unmet need strong enough? A venture requires significant time and resources. The unmet need must justify that investment. If existing treatments already cover the need adequately, a venture is hard to sustain.
Is there a realistic development path? Strong science alone is not enough. You need a credible regulatory pathway, a manufacturable product, and a fundable development plan.
Do you need control over access and pricing? A licence hands control to another party. A venture keeps it with you. In socially responsible drug development, this distinction is often the deciding factor.
Do you want to stay in academia? The traditional spin-off route often requires you to leave your academic role. That is not realistic for most researchers. But staying in academia does not mean losing control over your project. A venture partner like Orfenix can manage the business side while you remain central to key scientific decisions. It does require time and commitment beyond your research. But it keeps you where your expertise matters most.
What is your risk appetite? A venture requires governance, funding, and long-term commitment. If your goal is a quick handoff, a licence or collaboration may serve you better.
There are no wrong answers. But being clear early prevents costly misalignments later.
Figure 2 highlight the key questions you need to ask before deciding on a socially responsible drug development venture.
Validate Your Idea
One of the most important steps before making a venture decision in socially responsible drug development is external validation. A Product Development Plan (PDP) for instance forces clarity on the key questions that determine feasibility. Some examples of what this could include are:
Define your Target Product Profile (TPP)
Start here. A TPP describes what your medicine needs to look like to reach patients. What indication? What patient population? What route of administration? What efficacy and safety profile do regulators and payers expect? This single document anchors all decisions that follow.
Determine your regulatory pathway
Not all medicines follow the same route to approval. Is your product a full new application, a generic, a hybrid, or a well-established use application? The EMA defines these routes clearly, each with different data requirements, timelines, and costs. Choosing the right pathway early saves years of unnecessary work.
Assess your protection position
How do you protect your product? Intellectual property through patents is one route. But for rare diseases, Orphan Designation offers ten years of market exclusivity and significant regulatory incentives. Know your protection options before you build a business case.
Build your business case
What is the addressable market? How many patients exist globally? What share can you realistically reach? Investors and funders want very meticulous answers to these questions before they even consider your proposal. In socially responsible drug development, these projections of course also includes affordability and access assumptions.
Validate externally
Don’t rely only on your own enthusiasm. Programs like the Netherlands Venture Challenge, government grants like MIT, and EIC Pathfinder offer structured validation. They test your assumptions with experienced evaluators. A rejection here is far cheaper than a failed venture later.
When Does a Socially Responsible Drug Development Venture Make Sense?
A venture decision in socially responsible drug development makes sense when three conditions align: the unmet need is serious and underserved, the business case is logical and investable, and you need to retain control over access and pricing. If you want to learn more about what socially responsible drug development entails, read our insight on the topic here.
Rare diseases, neglected conditions, and drug repurposing projects often lack commercial interest from large pharma. A dedicated venture fills that gap, but only when the addressable market, development costs, and protection position add up to a case that mission-aligned investors can support. Without a credible business case, even the best science stalls.
Figure 3 illustrates the overlap of the three conditions that need to align for a socially responsible drug development venture decision.
When is a venture not the right choice?
Sometimes proving clinical value is enough. A well-designed clinical study can trigger reimbursement decisions directly. In that case, a full venture adds unnecessary complexity rather than solving a real access problem.
A venture is also not the right choice when your main goal is a quick handoff to an existing party, when commercial partners are already well-positioned to serve patients affordably, or when development costs require a large pharma partnership to be feasible at all.
How Orfenix can help
If clinical proof alone isn’t enough, if getting your therapy to patients requires a viable commercial structure built on socially responsible principles, that’s where we come in.
We have experience setting up ventures and designing governance structures that keep patient access central. We know what it takes to move from promising research to a fundable, feasible product. Before you commit to a venture path, we look at structural feasibility: Is the business case sound? Is the development plan realistic? Are the right partners in place?
We can support you with feasibility assessments, Product Development Plans, governance design, venture development and management, and partnership structure design (including Public Private Partnership setups) before you commit anything.
If you want to get your therapy to patients and need a partner to think through the non-scientific pieces, we’d like to talk.
Reach out to learn more!
